Strong IPO Listing: Anthem Biosciences Shares Gain 27% on NSE Debut

by Priya Bhatiya

Posted on July 21, 2025

Anthem Biosciences Shares: Strong Market Debut

Key Listing Details

• Anthem Biosciences Limited made a robust stock market debut on July 21, 2025, with shares listing at ₹723.05 per share on the National Stock Exchange (NSE).
• This opening price was 26.85% higher than the IPO issue price of ₹570 per share.
• On the Bombay Stock Exchange (BSE), shares opened at ₹723.10, also reflecting a similar premium.
• The listing price was slightly below some analysts’ grey market premium (GMP) expectations, which suggested a debut at around ₹749 per share.

IPO Subscription and Price Band

• The IPO price band was set between ₹540 and ₹570 per share.
• The initial public offering (IPO) was entirely an offer for sale (OFS) of 5.96 crore shares, raising ₹3,395 crore for selling shareholders—no fresh equity was issued, and the company itself did not receive the proceeds.
• Investor response was strong, with the IPO being subscribed nearly 64–67.4 times overall, primarily led by qualified institutional buyers.

Company Overview

• Anthem Biosciences, founded in 2006, is a contract research, development, and manufacturing organisation (CRDMO), serving global pharma and biotech clients.
• The company is known for providing end-to-end solutions across the drug discovery and manufacturing value chain.

Financial and Market Snapshot

IPO Highlights

• IPO Dates: July 14–16, 2025.
• Listing Date: July 21, 2025.
• Price Band: ₹540–₹570 per share.
• Face Value: ₹2 per share.
• Lot Size: 26 shares per lot (minimum investment: ₹14,040).
• Issue Size: ₹3,395 crore; entire offer was an Offer for Sale (OFS) of 5.96 crore shares—no fresh capital raised for the company.
• Lead Managers: JM Financial, Citigroup Global Markets India, J.P. Morgan India, Nomura Financial Advisory.
• Registrar: Kfin Technologies.

Investor Notes

• The market capitalisation at the time of listing was around ₹40,610 crore.
• Ahead of listing, Anthem Biosciences raised about ₹1,016 crore from anchor investors.
• The offering attracted wide participation from institutional, high-net-worth, and retail investors.

Anthem Biosciences’ strong debut highlights significant investor confidence and demand in the Indian primary equity market in 2025.

Ref: Anthem Biosciences lists at 27% premium; should you book profit or hold?